Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMGEL vs ALTABAX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It also has anti-inflammatory and immunomodulatory effects, including inhibition of neutrophil chemotaxis and modulation of cytokine production.
Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.
Treatment of acne vulgaris (FDA-approved),Topical treatment of inflammatory acne (FDA-approved),Ophthalmic infections: prophylaxis of neonatal conjunctivitis (off-label),Treatment of bacterial infections of the skin (off-label)
FDA-approved for topical treatment of impetigo due to Staphylococcus aureus and Streptococcus pyogenes in patients aged 9 months and older
Topical application of a thin layer to affected area twice daily; oral administration not applicable.
1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².
Terminal elimination half-life: 1.5–2.0 hours in adults with normal renal function, prolonged in renal impairment (up to 6–8 hours with GFR <30 m L/min).
Terminal half-life is approximately 11-14 hours in adults after topical application, supporting twice-daily dosing.
Metabolized primarily in the liver via cytochrome P450 3A4 (CYP3A4) isoenzyme; excreted mainly in bile and feces.
Retapamulin undergoes hepatic metabolism primarily via cytochrome P450 (CYP) isoenzymes, including CYP3A4, and is excreted in feces and urine.
Almost entirely renal (90-95% as unchanged drug via glomerular filtration and tubular secretion), with less than 5% fecal or biliary elimination.
Retapamulin is primarily eliminated via the fecal route (96.5% of dose), with minimal renal excretion (<0.5% of dose).
70–80%, primarily to albumin.
Retapamulin is approximately 94% bound to human plasma proteins, primarily albumin.
0.9–1.1 L/kg; indicates extensive extravascular distribution.
Volume of distribution after IV administration is approximately 3.1 L/kg, indicating extensive tissue distribution.
Topical: systemic absorption minimal (approximately 1–5%); oral: 50–60% (first-pass metabolism); intravenous: 100%.
Systemic bioavailability after topical application is low and highly variable, with mean values <2% in adults.
No dosage adjustment required for topical use.
No dose adjustment required for renal impairment as systemic absorption is negligible.
No dosage adjustment required for topical use.
No dose adjustment required for hepatic impairment as systemic absorption is negligible.
Safety and efficacy in children <12 years not established; for children ≥12 years, apply thin layer topically twice daily.
Children 9 months and older: Apply 1% ointment to affected area twice daily for 5 days. Maximum treatment area 100 cm². For children under 9 months: safety and efficacy not established.
No specific dose adjustment; use caution due to potential skin atrophy in elderly.
No specific dose adjustment required. Use same as adult dosing due to minimal systemic absorption.
No FDA black box warning for topical erythromycin.
No black box warnings.
May cause irritation, burning, stinging, or dryness at application site,Use with caution in patients with known hypersensitivity to erythromycin or any macrolide antibiotic,Superinfection may occur with prolonged use,Potential for bacterial resistance with prolonged use
Not for use on mucous membranes (e.g., eyes, mouth, vagina).,May cause application site reactions (e.g., pruritus, erythema, pain).,Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including retapamulin.,Prolonged use may result in overgrowth of nonsusceptible organisms.
Hypersensitivity to erythromycin or any component of the formulation,Not for use in patients with known hepatic impairment (relative contraindication for systemic use, but topical use is generally safe)
Hypersensitivity to retapamulin or any component of the formulation.
No known food interactions. Avoid alcohol as it may increase risk of gastrointestinal irritation if oral salicylates are also used.
None known. Topical application with negligible systemic absorption; no dietary restrictions.
EMGEL contains tetracycline-class antibiotic. Tetracyclines are associated with fetal risk primarily in second and third trimesters due to incorporation into developing bone and teeth, causing permanent discoloration and enamel hypoplasia; also associated with impaired skeletal growth and reversible inhibition of bone growth. First-trimester exposure is not associated with major malformations but may affect early bone and tooth development. Use contraindicated after first trimester.
No adequate and well-controlled studies in pregnant women. Animal studies: oral doses up to 50 mg/kg/day in rats (0.8 times MRHD based on AUC) and 40 mg/kg/day in rabbits (1.6 times MRHD) showed no fetal harm. However, systemic absorption after topical application is minimal, so fetal exposure is negligible. Risk cannot be ruled out; classify as pregnancy category B.
Tetracyclines are excreted into breast milk in low concentrations (M/P ratio approximately 0.5-0.8). Theoretical risk of dental staining and bone growth inhibition in nursing infants exists, but absorption of tetracyclines from milk is limited due to chelation with calcium. Caution is advised; alternative therapies preferred.
Not known if retapamulin is excreted in human milk. Systemic absorption is negligible after topical use, so risk to infant is likely low. M/P ratio not determined. Caution if applied to breast area to avoid infant ingestion.
No dose adjustment required for EMGEL in pregnancy; however, tetracyclines are contraindicated after first trimester. Pregnancy may alter pharmacokinetics (e.g., increased volume of distribution, decreased plasma protein binding) but no specific dose adjustment recommended due to contraindication. Use only when no alternative and clearly needed.
No dose adjustment needed. Pharmacokinetics unchanged as systemic absorption is minimal (<1%) and not affected by pregnancy. Standard dosing: apply thin layer to affected area twice daily for 5 days.
Apply sparingly to affected area; avoid contact with eyes, mucous membranes, and open wounds. Monitor for systemic absorption if used on large body surface areas. Use caution in patients with renal impairment due to potential for salicylate toxicity. Do not use with other topical preparations containing methyl salicylate.
Retapamulin (Altabax) is a topical pleuromutilin antibiotic indicated for impetigo due to S. aureus or S. pyogenes. Apply to lesions twice daily for 5 days. Avoid contact with eyes, mouth, or mucous membranes. No systemic absorption significant; safe for use in children ≥9 months. Do not use on open wounds or burns. Monitor for local irritation; discontinue if hypersensitivity occurs.
Wash hands before and after application.,Apply only to intact skin, not on wounds or damaged skin.,Do not use with heating pads or bandages unless directed by doctor.,Avoid sun exposure to treated area as it may cause photosensitivity.,Discontinue if rash or irritation occurs and consult doctor.
Apply a thin layer to the affected area twice daily for 5 days, even if symptoms improve.,Wash hands before and after application unless treating hand lesions.,Do not cover the area with bandages unless instructed by your doctor.,Avoid getting the ointment in your eyes, nose, mouth, or on vaginal area.,Stop use and inform your doctor if you develop severe irritation, redness, or swelling.,Store at room temperature away from heat and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMGEL vs ALTABAX, answered by our medical review team.
EMGEL is a Topical Antibiotic that works by Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It also has anti-inflammatory and immunomodulatory effects, including inhibition of neutrophil chemotaxis and modulation of cytokine production.. ALTABAX is a Topical Antibiotic that works by Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMGEL and ALTABAX depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMGEL is: Topical application of a thin layer to affected area twice daily; oral administration not applicable.. The standard adult dose of ALTABAX is: 1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMGEL and ALTABAX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMGEL is classified as Category C. EMGEL contains tetracycline-class antibiotic. Tetracyclines are associated with fetal risk primarily in second and third trimesters due to incorporation into developing bone and te. ALTABAX is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies: oral doses up to 50 mg/kg/day in rats (0.8 times MRHD based on AUC) and 40 mg/kg/day in rabbits (1.6 time. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.